-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Climb Bio, Maintains $8 Price Target

Benzinga·04/08/2026 09:39:12
Listen to the news
BTIG analyst Julian Harrison reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $8 price target.